Human vaccine data release jumpstarts biotechs bid for RNA drugs

first_img Email Human vaccine data release jump-starts biotech’s bid for RNA drugs Originally published by Endpoints News.The executive team at Moderna raised a cheer today after publishing their first early snapshot of human efficacy data that demonstrate their messenger RNA tech works — at least on the first try.The biotech tested their H10N8 flu vaccine on a small group of 31 subjects, looking at their response in two different measures. All demonstrated a sufficient immune response to fight off the virus in the first measure, and all but 3 in the second, for a total of 23 who received the vaccine.  None of the 8 subjects who received a placebo responded. The biotech Moderna delivers messenger RNA (blue) into cells to be translated into proteins by ribosomes. This mysterious $2 billion biotech is revealing the secrets behind its new drugs and vaccines Read more… Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe What if #mrna could be a drug? Not so crazy now. A huge thank you to the @moderna_tx team. They are amazing.— stephane bancel (@sbancel) April 27, 2017It is still early days at Moderna, which has to prove that it can develop mRNA drugs for some of the more lucrative therapies than the frontrunning vaccines. That will take some time. But Moderna’s been doing much more to outline what programs it has in the pipeline, and when it can discuss more about the data.“I’m cautiously optimistic this could be a really important addition to our vaccine arsenal,” Barney Graham, deputy director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases, told the Wall Street Journal. He added that RNA is unstable, leaving him eager to see more mature data on how this works.Bancel and his fellow execs at Moderna may have a long way to go, but they’re confident that they took a big step along the journey today. From now on, it’s all about clinical data at Moderna.center_img Click to view the privacy policy. Required fields are indicated by an asterisk (*) V. Altounian/Science Moderna’s board has already decided not to seek an IPO this year, and Bancel adds that there’s no definitive plans set for 2018 either. What he would like to do, he says, is add new pieces to the pipeline — new verticals to the three he’s already outlined — adding more data on the potential mRNA has to create a new pathway on drug development for a wide array of diseases. Then, have something substantial that proves what they can do, he’ll set out to convince investors.The huge amount of cash raised to date and Moderna’s plans to prove the principles behind its science — focusing on vaccines as the most likely initial demonstration program that could prove that mRNA can safely work — has also triggered more than a little schadenfreude for a company that is often billed as mysterious and lavishly funded. STAT picked up on that, reporting a battery of mostly anonymous criticism about its tough work environment and lofty claims, laying into the biotech at every turn. By John Carroll, Endpoints NewsApr. 28, 2017 , 3:15 PM Sign up for our daily newsletter Get more great content like this delivered right to you! Country Typically, evidence of Phase I success in a vaccine study — which followed a number of animal studies — wouldn’t attract much attention for your average biotech. But there’s nothing average about Moderna. CEO Stéphane Bancel and his team have attracted $1.9 billion to create a company that’s building a pipeline around messenger RNA, one of a handful of players looking to coax cells to produce proteins to fight disease. And that’s a massive amount for a company that just showed human proof of concept data.This vaccine is not pointed toward commercialization, Bancel told me Thursday afternoon. It’s a demonstration project. The goal was to start out with “low biology risk where we knew where the goal post was before we started the trial.”last_img read more